Home/Pipeline/Retifanlimab

Retifanlimab

Various Cancers

Phase 2/3Active

Key Facts

Indication

Various Cancers

Phase

Phase 2/3

Status

Active

Company

Eli Lilly

About Eli Lilly

Eli Lilly is one of the world's largest pharmaceutical companies with over 145 years of experience in developing life-changing medicines. The company has achieved significant recent success with GLP-1 receptor agonists for diabetes and weight management, generating substantial revenue growth. Lilly continues to invest heavily in R&D across key therapeutic areas including diabetes, oncology, autoimmune diseases, and neurodegeneration, with a robust pipeline of innovative treatments in development.

View full company profile

Therapeutic Areas

Diabetes Oncology Immunology Neuroscience Obesity Cardiovascular

Other Various Cancers Drugs

Drug	Company	Phase	Status
Imfinzi (durvalumab)	AstraZeneca	Approved	Commercial
Lynparza (olaparib)	Merck	Commercial	Active
Oncology Portfolio	Pfizer	Phase 1-3	Multiple Active Programs
PD-1 Inhibitor	Akeso	Phase 2/3	Active
Mitoxantrone Liposome	CSPC Pharmaceutical Group Limited	Phase 3	Active
Biosimilar Bevacizumab	Cipla	Commercial	Active
Tazverik (tazemetostat)	Eisai	Commercial	Discontinuation announced
Oncology Generics	Aurobindo Pharma	Commercial	Active
Opdivo (nivolumab)	Ono Pharmaceutical	Approved	Commercial
Oncology APIs (e.g., Sorafenib, Lenalidomide)	Laurus Labs	Commercial/Filed	Active
Tumor Marker Portfolio (PSA, CA125, etc.)	H.U. Group Holdings	Commercial	Active
Logic-gated Switch-DARPins	Molecular Partners	Preclinical	Platform